Dextrorphan-d3 (tartrate) (Synonyms: d-3-hydroxy-N-Methylmorphinan tartrate-d3) |
| Catalog No.GC47203 |
A Certified Reference Material
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1426174-16-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dextrorphan-d3 (tartrate) is intended for use as an internal standard for the quantification of dextrorphan (tartrate) by GC- or LC-MS. Dextrorphan is categorized as an arylcyclohexylamine and is a metabolite of dextromethorphan (hydrobromide hydrate) , an antitussive found in cough medicines. Dextrorphan, while also having antitussive activity, is psychoactive, leading to the abuse of cough medicines containing the parent compound.1,2 Dextrorphan antagonizes NMDA and µ-opioid receptors (Kis = 54 and 420 nM, respectively) and inhibits norepinephrine and serotonin transporters (Kis = 340 and 401 nM, respectively).3,4,5 This product is intended for research and forensic applications.
1.Shin, E.J., Lee, P.H., Kim, H.J., et al.Neuropsychotoxicity of abused drugs: Potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effectsJournal of Pharmacological Sciences106(1)22-27(2008) 2.Chomchai, C., and Manaboriboon, B.Stimulant methamphetamine and dextromethorphan use among Thai adolescents: implications for health of women and childrenJ.Med.Toxicol.8(3)291-294(2012) 3.LePage, K.T., Ishmael, J.E., Low, C.M., et al.Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptorsNeuropharmacology49(1)1-16(2005) 4.Kaczor, A.A., Kijkowska-Murak, U.A., and Matosiuk, S.Theoretical studies on the structure and symmetry of the transmembrane region of glutamatergic GluR5 receptorJournal of Medicinal Chemistry51(13)3765-3776(2008) 5.Codd, E.E., Shank, R.P., Schupsky, J.J., et al.Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociceptionJ. Pharmacol. Exp. Ther.274(3)1263-1270(1995)
| Cas No. | 1426174-16-4 | SDF | |
| Synonyms | d-3-hydroxy-N-Methylmorphinan tartrate-d3 | ||
| Canonical SMILES | OC1=CC=C2C[C@H](N3C([2H])([2H])[2H])[C@@]4([H])CCCC[C@@]4(CC3)C2=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O | ||
| Formula | C17H20D3NO.C4H6O6 | M.Wt | 410.5 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4361 mL | 12.1803 mL | 24.3605 mL |
| 5 mM | 487.2 μL | 2.4361 mL | 4.8721 mL |
| 10 mM | 243.6 μL | 1.218 mL | 2.4361 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *